Abstract
Mucocutaneous adverse events are commonly observed under immune checkpoint inhibitors (ICIs) therapy. Here, we report the case of a 43-year-old male p......
小提示：本篇文献需要登录阅读全文，点击跳转登录
Full Text Link
